IR Banner

Press Releases

Date Title and Summary Additional Format
Aug 9, 2022
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24 Patients Anticipated from OraGrowtH212 Trial -- -- Cash Runway into Second Quarter 2024 -- AUSTIN,
Jul 27, 2022
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
AUSTIN, Texas , July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022 . The company will host a conference call and
Jul 26, 2022
CEO Update: Interview with Lumos Pharma’s Chief Medical Officer, David B. Karpf, M.D.
Lumos Pharma CMO, David B. Karpf, M.D., walks us through his background and perspective on LUM-201. Q: When did you know you wanted to go into medicine – what drove you to that profession? A: My dad was an exceptional doctor, so I knew at age 5 that I wanted to be a physician.
May 16, 2022
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas , May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences: Event: H.C.
May 10, 2022
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold-- --Clinical Collaboration Initiated with Massachusetts General
May 5, 2022
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA AUSTIN, Texas , May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare
Apr 26, 2022
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
AUSTIN, Tex. , April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results after market close on Tuesday, May 10, 2022 . The company will host a conference call and webcast
Apr 11, 2022
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
-    Interim Data Anticipated by End of 2022    - -   Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 - AUSTIN, Texas , April 11, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare
Mar 23, 2022
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
AUSTIN, Texas , March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew , PhD, President and Chief Scientific Officer of Lumos Pharma , will participate in a panel
Mar 10, 2022
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
Data from interim analyses of Phase 2 OraGrowtH210 Trial and PK/PD OraGrowtH212 Trial evaluating oral LUM-201 in PGHD anticipated by the end of 2022 AUSTIN, Texas , March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on
Displaying 41 - 50 of 98